http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Veracyte Announces Third Quarter 2021 Financial Results
-
Veracyte (VCYT) Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
-
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
-
Veracyte (VCYT) Announces New Publication Reinforcing Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
-
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
-
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
-
Veracyte (VCYT) Announces New Data Validating Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
-
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
-
Veracyte (VCYT) Announces New Clinical Utility Data Confirm its Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
-
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
-
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
-
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
-
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
-
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
-
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
-
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
-
Veracyte Completes Acquisition of HalioDx
-
Veracyte Announces Second Quarter 2021 Financial Results
-
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
-
Veracyte (VCYT) Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer
-
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
-
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
-
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
-
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
-
Veracyte (VCYT) Announces New Data Published in JAMA Oncology Demonstrate Prognostic Utility of its Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
-
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
-
Veracyte (VCYT) Receives Final Medicare Coverage Policies for Decipher Bladder
-
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte (VCYT) to Acquire HalioDx
-
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte (VCYT) Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
-
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
-
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
-
Veracyte (VCYT) Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
-
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
-
Veracyte (VCYT) Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
-
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
-
Veracyte, Inc. Announces CEO Succession Plan
-
Veracyte Announces First Quarter 2021 Financial Results
-
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
-
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
-
Veracyte (VCYT) Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis

